Many cancers have inactivating mutations in their TGF-β receptor55,56 or SMAD complex pathways57, discontinuing the tumor suppressive effects of TGF-β signaling especially in cells already harboring oncogenic mutations (premalignant). This evidence concerns the gene TGFB1 and cancer.